Immunomodulatory effects of viscum album extracts on natural killer cells: Review of clinical trials

Forschende Komplementarmedizin

Volumn 17, Issue 2, 2010, Pages 63-73

  Braedel Ruoff, Sibylla ^a  

^a Braedel Scientific Consulting   (Germany)

Author keywords

Biological response modifier; Cancer; Immunomodulation; Immunotherapy; Iscador ; Mistletoe; NK cell; Viscum album L.

Indexed keywords

IMMUNOLOGIC FACTOR; PLANT EXTRACT; VEGETABLE PROTEIN; VISCUM ALBUM PEPTIDE;

CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG EFFECT; HUMAN; IMMUNOLOGY; NATURAL KILLER CELL; NEOPLASM; PHYTOTHERAPY; REVIEW; VISCUM ALBUM;

CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC FACTORS; KILLER CELLS, NATURAL; NEOPLASMS; PHYTOTHERAPY; PLANT EXTRACTS; PLANT PROTEINS; VISCUM ALBUM;

EID: 77952920116     PISSN: 16614119     EISSN: 16614127     Source Type: Journal    
DOI: 10.1159/000288702     Document Type: Review

References (145)

1. Kienle GS, Kiene H: Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts. Eur J Med Res 2007;12:103-119.
2. Franz H, Ziska P, Kindt A: Isolation and properties of three lectins from mistletoe (Viscum album L.). Biochem J 1981;195:481-484.
3. Winterfeld K, Kronenthaler A: Zur Chemie des blutdrucksenkenden Bestandteiles der Mistel (VIS-CUM ALBUM).III. Mitteilung. Archiv Pharmaz 1942;280:103-115.
4. Winterfeld K, Bijl LH: Viscotoxin, ein neuer Inhaltsstoff der Mistel (VISCUM ALBUM L.). Justus Liebigs Annalen der Chemie 1948;561:107-115.
5. Klett CY, Anderer FA: Activation of natural killer cell cytotoxicity of human blood monocytes by a low molecular weight component from viscum album extract. Arzneimittelforschung 1989; 39:1580-1585.
6. Mueller EA, Anderer FA: A Viscum album oligosaccharide activating human natural cytotoxicity is an interferon gamma inducer. Cancer Immunol Immunother 1990;32:221-227.
7. Urech K, Scher JM, Hostanska K, Becker H: Apoptosis inducing activity of viscin, a lipophilic extract from Viscum album L. J Pharm Pharmacol 2005; 57:101-109.
8. Büssing A: Mistletoe. The Genus Viscum. Amsterdam, Hardwood Academic, 2000, pp 122-182.
9. Büssing A, Azhari T, Ostendorp H, Lehnert A, Schweizer K: Viscum album L. extracts reduce sister chromatid exchanges in cultured peripheral blood mononuclear cells. Eur J Cancer 1994; 30A:1836-1841.
10. Büssing A, Regnery A, Schweizer K: Effects of Viscum album L. on cyclophosphamide-treated peripheral blood mononuclear cells in vitro: sister chromatid exchanges and activation/proliferation marker expression. Cancer Lett 1995;94:199-205.
11. Büssing A, Jungmann H, Suzart K, Schweizer K: Suppression of sister chromatid exchange-inducing DNA lesions in cultured peripheral blood mononuclear cells by VISCUM ALBUM L. J Exp Clin Cancer Res 1996;15:107-114.
12. Braun JM, Ko HL, Schierholz JM, Beuth J: Standardized mistletoe extract augments immune response and down-regulates local and metastatic tumor growth in murine models. Anticancer Res 2002;22:4187-4190.
13. Elluru SR, van Huyen J-PD, Wootla B, Delignat S, Prost F, Negi VS, Kaveri SV: Tumor regressive effects of VISCUM ALBUM preparations - exploration of immunomodulatory mechanisms. Medicina (Buenos Aires) 2007;67(supl II):85-89.
14. Maldacker J: Preclinical investigations with mistletoe (Viscum album L.) extract Iscador. Arzneimit-telforschung 2006;56:497-507.
15. Büssing A, Suzart K, Bergmann J, Pfuller U, Schietzel M, Schweizer K: Induction of apoptosis in human lymphocytes treated with Viscum album L. is mediated by the mistletoe lectins. Cancer Lett 1996;99:59-72. (Pubitemid 26030353)
16. Büssing A, Vervecken W, Wagner M, Wagner B, Pfuller U, Schietzel M: Expression of mitochondrial Apo2.7 molecules and caspase-3 activation in human lymphocytes treated with the ribosome-inhibiting mistletoe lectins and the cell membrane permeabilizing viscotoxins. Cytometry 1999;37: 133-139.
17. Janssen O, Scheffler A, Kabelitz D: In vitro effects of mistletoe extracts and mistletoe lectins. Cytotoxicity towards tumor cells due to the induction of programmed cell death (apoptosis). Arzneimittel-forschung 1993;43:1221-1227.
18. Büssing A, Schaller G, Pfuller U: Generation of reactive oxygen intermediates (ROI) by the thionins from Viscum album L. Anticancer Res 1998;18: 4291-4296.
19. Kuttan G, Kuttan R: Immunological mechanism of action of the tumor reducing peptide from mistletoe extract (NSC 635089) cellular proliferation. Cancer Lett 1992;66:123-130.
20. Stein GM, Berg PA: Modulation of cellular and humoral immune responses during exposure of healthy individuals to an aqueous mistletoe extract. Eur J Med Res 1998;3:307-314.
21. Hamprecht K, Handgretinger R, Voetsch W, Anderer FA: Mediation of human NK-activity by components in extracts of Viscum album. Int J Immunopharmacol 1987;9:199-209.
22. Mueller EA, Hamprecht K, Anderer FA: Biochemical characterization of a component in extracts of Viscum album enhancing human NK cytotoxicity. Immunopharmacology 1989;17:11-18.
23. Elluru SR, Van Huyen JP, Delignat S, Kazatchkine MD, Friboulet A, Kaveri SV, Bayry J: Induction of maturation and activation of human dendritic cells: a mechanism underlying the beneficial effect of Viscum album as complimentary therapy in cancer. BMC Cancer 2008;8:161.
24. Stein GM, Bussing A, Schietzel M: Stimulation of the maturation of dendritic cells in vitro by a fermented mistletoe extract. Anticancer Res 2002; 22:4215-4219. (Pubitemid 36134460)
25. Nikolai G, Friedl P, Werner M, Niggemann B, Zanker KS: Effect of a mistletoe extract (Iscador QuFrF) on viability and migratory behavior of human peripheral CD4+ and CD8+ T lymphocytes in three-dimensional collagen lattices. In Vitro Cell Dev Biol Anim 1997;33:710-716.
26. Stein GM, Berg PA: Evaluation of the stimulatory activity of a fermented mistletoe lectin-1 free mistletoe extract on T-helper cells and monocytes in healthy individuals in vitro. Arzneimittelforschung 1996;46:635-639.
27. Robertson MJ: Role of chemokines in the biology of natural killer cells. J Leukoc Biol 2002;71:173-183.
28. Kiessling R, Klein E, Wigzell H: 'Natural' killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 1975;5:112-117.
29. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K: Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000;356:1795-1799.
30. Wallace ME, Smyth MJ: The role of natural killer cells in tumor control - effectors and regulators of adaptive immunity. Springer Semin Immunopathol 2005;27:49-64.
31. Cerwenka A, Lanier LL: Ligands for natural killer cell receptors: redundancy or specificity. Immunol Rev 2001;181:158-169.
32. Moretta L, Bottino C, Pende D, Vitale M, Mingari MC, Moretta A: Different checkpoints in human NK-cell activation. Trends Immunol 2004;25: 670-676.
33. Vivier E, Nunes JA, Vely F: Natural killer cell signaling pathways. Science 2004;306:1517-1519.
34. Karre K, Ljunggren HG, Piontek G, Kiessling R: Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986;319:675-678.
35. Ljunggren HG, Karre K: Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med 1985; 162:1745-1759.
36. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T: Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285:727-729.
37. Hayakawa Y, Smyth MJ: NKG2D and cytotoxic effector function in tumor immune surveillance. Semin Immunol 2006;18:176-185.
38. Trapani JA, Smyth MJ: Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2002;2:735-747.
39. Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, van den Brink MR, Yagita H: Nature's TRAIL - on a path to cancer immunotherapy. Immunity 2003; 18:1-6.
40. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP: Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999;17:189-220.
41. Di Santo JP: Natural killer cell developmental pathways: a question of balance. Annu Rev Immunol 2006;24:257-286.
42. Trinchieri G: Biology of natural killer cells. Adv Immunol 1989;47:187-376.
43. Degli-Esposti MA, Smyth MJ: Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol 2005;5:112-124.
44. Di Santo JP: Natural killer cells: diversity in search of a niche. Nat Immunol 2008;9:473-475.
45. Moretta L, Ferlazzo G, Bottino C, Vitale M, Pende D, Mingari MC, Moretta A: Effector and regulatory events during natural killer-dendritic cell interactions. Immunol Rev 2006;214:219-228.
46. Yokoyama WM: Mistaken notions about natural killer cells. Nat Immunol 2008;9:481-485.
47. Mailliard RB, Son YI, Redlinger R, Coates PT, Giermasz A, Morel PA, Storkus WJ, Kalinski P: Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol 2003;171:2366-2373.
48. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S: Functions of natural killer cells. Nat Immunol 2008;9:503-510.
49. Zhu HG, Zollner TM, Klein-Franke A, Anderer FA: Enhancement of MHC-unrestricted cytotoxic activity of human CD56+ CD3- natural killer (NK) cells and CD3+ T cells by rhamnogalacturonan: target cell specificity and activity against NK-insensitive targets. J Cancer Res Clin Oncol 1994;120:383-388.
50. Antony S, Kuttan R, Kuttan G: Effect of viscum album in the inhibition of lung metastasis in mice induced by B16F10 melanoma cells. J Exp Clin Cancer Res 1997;16:159-162. (Pubitemid 27376574)
51. Yoon TJ, Yoo YC, Kang TB, Baek YJ, Huh CS, Song SK, Lee KH, Azuma I, Kim JB: Prophylactic effect of Korean mistletoe (Viscum album coloratum) extract on tumor metastasis is mediated by enhancement of NK cell activity. Int J Immunopharmacol 1998;20:163-172.
52. Antony S, Kuttan R, Kuttan G: Role of natural killer cells in iscador mediated inhibition of metastasis by adoptive immunotherapy. Immunol Invest 2000;29:219-231.
53. Hülsen H, Born U: Einfluss von Mistelpräparaten auf die In-vitro-Aktivität der natürlichen Killerzellen von Krebspatienten (Teil 2). Therapeutikon 1993;7:434-439.
54. Kienle GS, Kiene H: Die Mistel in der Onkologie - Fakten und konzeptionelle Grundlagen. Stuttgart, Schattauer, 2003, pp 1-749.
55. Salzer G: Pleura carcinosis. Cytomorphological findings with the mistletoe preparation iscador and other pharmaceuticals. Oncology 1986;43(suppl 1):66-70.
56. Salzer G, Popp W: Die lokale Iscadorbehandlung der Pleurakarzinose; in Ed Jungi WF, Seen H-J (Hrsg): Krebs und Alternativmedizin II, vol II Berlin, Springer, 1990, pp 36-49.
57. Wagner R: Eine Praxisbeobachtung 1993-1996. Iscador-Informationen. Ostfildern, Verein für Krebsforschung, 1996, pp 1-42.
58. Hajto T, Hostanska K: Stimulierung der natürlichen Tumorresistenz durch die Lektinoptimierung eines in der Klinik angewandten Mistelextraktes (Iscador). Erfahrungsheilkunde 1991;3a:242-245.
59. Hajto T, Hostanska K, Fornalski M, Kirsch A: Antitumorale Aktivität des immunmodulatorisch wirkenden Beta-galatkosidspezifische Mistellektins bei der klinischen Anwendung von Mistelextrakten (Iscador). Dtsch Z Onkol 1991;23:1-6.
60. Kuehn JJ, Fornalski M: Beeinflussung immunkompetenter Zellen des peripheren Blutes durch VISCUM ALBUM (Iscador M) bei Patientinnen mit Mammakarzinom; in Scheer R, Becker H, Berg PA (Hrsg): Grundlagen der Misteltherapie: Aktueller Stand der Forschung und klinische Anwendung. Stuttgart, Hippokrates, 1996, pp 366-379.
61. Kuehn JJ, Fornalski M: Immunologische Reaktionen im peripheren Blut bei Patientinnen mit Mammakarzinom unter VISCUM ALBUM-Therapie (Iscador M); in Kropiunnig U, Stacher A (Hrsg): Ganzheitsmedizin und Psychoneuroimmunologie, Vierter Wiener Dialog. Wien, Facultas, 1997, pp 396-407.
62. Kovacs E: Serum levels of IL-12 and the production of IFN-gamma, IL-2 and IL-4 by peripheral blood mononuclear cells (PBMC) in cancer patients treated with Viscum album extract. Biomed Pharmacother 2000;54:305-310.
63. Kovacs E, Hajto T, Hostanska K: Improvement of DNA repair in lymphocytes of breast cancer patients treated with Viscum album extract (Iscador). Eur J Cancer 1991;27:1672-1676.
64. Hajto T, Lanzrein C: Natural killer and antibodydependent cell-mediated cytotoxicity activities and large granular lymphocyte frequencies in Viscum album-treated breast cancer patients. Oncology 1986;43:93-97.
65. Lennard TW, Shenton BK, Borzotta A, Donnelly PK, White M, Gerrie LM, Proud G, Taylor RM: The influence of surgical operations on components of the human immune system. Br J Surg 1985; 72:771-776.
66. Greenfeld K, Avraham R, Benish M, Goldfarb Y, Rosenne E, Shapira Y, Rudich T, Ben Eliyahu S: Immune suppression while awaiting surgery and following it: dissociations between plasma cytokine levels, their induced production, and NK cell cytotoxicity. Brain Behav Immun 2007;21:503-513.
67. Lin CY, Bai DJ, Yuan HY, Wang K, Yang GL, Hu MB, Wu ZQ, Li Y: Perioperative cimetidine administration promotes peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer: Results of a randomized controlled clinical trial. World J Gastroenterol 2004;10:136-142.
68. Pollock RE, Lotzova E, Stanford SD: Surgical stress impairs natural killer cell programming of tumor for lysis in patients with sarcomas and other solid tumors. Cancer 1992;70:2192-2202.
69. Kondo E, Koda K, Takiguchi N, Oda K, Seike K, Ishizuka M, Miyazaki M: Preoperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for colon cancer. Dig Surg 2003;20:445-451.
70. Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N, Yagita H, Okumura K: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gammadependent natural killer cell protection from tumor metastasis. J Exp Med 2001;193:661-670. (Pubitemid 32524460)
71. Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, Iwakura Y, Yagita H, Okumura K: Involvement of tumor necrosis factorrelated apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001;7:94-100. (Pubitemid 32095647)
72. Vallejo R, Hord ED, Barna SA, Santiago-Palma J, Ahmed S: Perioperative immunosuppression in cancer patients. J Environ Pathol Toxicol Oncol 2003;22:139-146.
73. Ben Eliyahu S, Page GG, Yirmiya R, Shakhar G: Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity. Int J Cancer 1999;80:880-888.
74. Melamed R, Rosenne E, Shakhar K, Schwartz Y, Abudarham N, Ben Eliyahu S: Marginating pulmonary-NK activity and resistance to experimental tumor metastasis: suppression by surgery and the prophylactic use of a beta-adrenergic antagonist and a prostaglandin synthesis inhibitor. Brain Behav Immun 2005;19:114-126.
75. Vujanovic NL, Basse P, Herberman RB, Whiteside TL: Antitumor functions of natural killer cells and control of metastases. Methods 1996;9:394-408.
76. Page GG, Ben Eliyahu S, Liebeskind JC: The role of LGL/NK cells in surgery-induced promotion of metastasis and its attenuation by morphine. Brain Behav Immun 1994;8:241-250.
77. Brossart P, Schmier JW, Kruger S, Willhauck M, Scheibenbogen C, Mohler T, Keilholz U: A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in periphe ral blood. Cancer Res 1995;55:4065-4068.
78. Ghossein RA, Carusone L, Bhattacharya S: Molecular detection of micrometastases and circulating tumor cells in melanoma prostatic and breast carcinomas. In Vivo 2000;14:237-250.
79. Pelkey TJ, Frierson HF Jr, Bruns DE: Molecular and immunological detection of circulating tumor cells and micrometastases from solid tumors. Clin Chem 1996;42:1369-1381.
80. Miyazono F, Natsugoe S, Takao S, Tokuda K, Kijima F, Aridome K, Hokita S, Baba M, Eizuru Y, Aikou T: Surgical maneuvers enhance molecular detection of circulating tumor cells during gastric cancer surgery. Ann Surg 2001;233:189-194.
81. Yamaguchi K, Takagi Y, Aoki S, Futamura M, Saji S: Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. Ann Surg 2000;232:58-65.
82. Büssing A, Bischof M, Hatzmann W, Bartzsch F, Soto-Vera D, Fronk E-M, Gmeindl M, Schietzel M, Stein GM: Beeinflussung der Granulozytenfunktion durch einmalige perioperative Mistelextrakt-Infusion. Dtsch Z Onkol 2004;36:148-153.
83. Schink M, Troger W, Dabidian A, Goyert A, Scheuerecker H, Meyer J, Fischer IU, Glaser F: Mistletoe extract reduces the surgical suppression of natural killer cell activity in cancer patients. a randomized phase III trial. Forsch Komplementmed 2007;14:9-17.
84. Augustin M, Bock PR, Hanisch J, Karasmann M, Schneider B: Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland. Arznei-mittelforschung 2005;55:38-49.
85. Bock PR, Hanisch J, Friedel WE, Matthes H: Treatment with a fermented mistletoe (Viscum album L.) extract as part of long-term supportive care in patients with primary non-metastatic colorectal carcinoma. Phytomedicine 2007;14:43.
86. Büssing A: Immune modulation using mistletoe (Viscum album L.) extracts Iscador. Arzneimittel-forschung / Drug Research 2006;56:508-515.
87. Kjaer M: Misteltoe (Iscador) therapy in stage IV renal adenocarcinoma. A phase II study in patients with measurable lung metastases. Acta Oncol 1989;28:489-494.
88. Matthes H, Friedel WE, Hanisch J, Karasmann M, Bock PR: Improvement of the palliative supportive care in pancreatic carcinoma patients with a fermented mistletoe (Viscum album L.) extract treatment. Phytomedicine 2007;14:54.
89. Horneber MA, Bueschel G, Huber R, Linde K, Rostock M: Mistletoe therapy in oncology. Cochrane Database Syst Rev 2008;CD003297.
90. Melzer J, Iten F, Hostanska K, Saller R: Efficacy and safety of mistletoe preparations (Viscum album) for patients with cancer diseases. A systematic review. Forsch Komplementmed 2009;16: 217-226.
91. Antony S, Kuttan R, Kuttan G: Inhibition of lung metastasis by adoptive immunotherapy using Iscador. Immunol Invest 1999;28:1-8.
92. Kuttan G, Kuttan R: Immunomodulatory activity of a peptide isolated from Viscum album extract (NSC 635 089). Immunol Invest 1992;21:285-296.
93. Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L: Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol 2008;9:486-494.
94. Walzer T, Blery M, Chaix J, Fuseri N, Chasson L, Robbins SH, Jaeger S, Andre P, Gauthier L, Daniel L, Chemin K, Morel Y, Dalod M, Imbert J, Pierres M, Moretta A, Romagne F, Vivier E: Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46. Proc Natl Acad Sci U S A 2007;104:3384-3389.
95. Cooper MA, Fehniger TA, Caligiuri MA: The biology of human natural killer-cell subsets. Trends Immunol 2001;22:633-640.
96. Ljunggren HG, Malmberg KJ: Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 2007;7:329-339.
97. Batoni G, Esin S, Favilli F, Pardini M, Bottai D, Maisetta G, Florio W, Campa M: Human CD-56bright and CD56dim natural killer cell subsets respond differentially to direct stimulation with Mycobacterium bovis bacillus Calmette-Guerin. Scand J Immunol 2005;62:498-506.
98. Aktas E, Kucuksezer UC, Bilgic S, Erten G, Deniz G: Relationship between CD107a expression and cytotoxic activity. Cell Immunol 2009;254:149-154.
99. Coulon A, Berkane E, Sautereau AM, Urech K, Rouge P, Lopez A: Modes of membrane interaction of a natural cysteine-rich peptide: viscotoxin A3. Biochim Biophys Acta 2002;1559:145-159.
100. Coulon A, Mosbah A, Lopez A, Sautereau AM, Schaller G, Urech K, Rouge P, Darbon H: Comparative membrane interaction study of viscotoxins A3, A2 and B from mistletoe (Viscum album) and connections with their structures. Biochem J 2003;374:71-78.
101. Tabiasco J, Pont F, Fournie JJ, Vercellone A: Mistletoe viscotoxins increase natural killer cell-media ted cytotoxicity. Eur J Biochem 2002;269: 2591-2600.
102. Mueller EA, Anderer FA: Chemical specificity of effector cell/tumor cell bridging by a Viscum album rhamnogalacturonan enhancing cytotoxicity of human NK cells. Immunopharmacology 1990; 19:69-77.
103. Klein-Franke A, Anderer FA: IL-12-mediated activation of MHC-unrestricted cytotoxicity of human PBMC subpopulations: synergic action of a plant rhamnogalacturonan. Anticancer Res 1995; 15:2511-2516.
104. Baxevanis CN, Voutsas IF, Soler MH, Gritzapis AD, Tsitsilonis OE, Stoeva S, Voelter W, Arsenis P, Papamichail M: Mistletoe lectin I-induced effects on human cytotoxic lymphocytes. I. Synergism with IL-2 in the induction of enhanced LAK cytotoxicity. Immunopharmacol Immunotoxicol 1998;20:355-372.
105. Hajto T, Hostanska K, Gabius HJ: Modulatory potency of the beta-galactoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients. Cancer Res 1989;49:4803-4808.
106. Hajto T, Hostanska K, Gabius HJ: Zytokine als Lektin-induzierte Mediatoren in der Misteltherapie. Therapeutikon 1990;4:136-145.
107. Hajto T, Hostanska K, Weber K, Zinke H, Fischer J, Mengs U, Lentzen H, Saller R: Effect of a recombinant lectin, Viscum album agglutinin on the secretion of interleukin-12 in cultured human peripheral blood mononuclear cells and on NK-cellmediated cytotoxicity of rat splenocytes in vitro and in vivo. Nat Immun 1998;16:34-46.
108. Ribereau-Gayon G, Jung ML, Frantz M, Anton R: Modulation of cytotoxicity and enhancement of cytokine release induced by Viscum album L. extracts or mistletoe lectins. Anticancer Drugs 1997;8(suppl 1):S3-S8.
109. Stein GM, Berg PA: Non-lectin component in a fermented extract from Viscum album l. grown on pines induces proliferation of lymphocytes from healthy and allergic individuals in vitro. Eur J Clin Pharmacol 1994;47:33-38.
110. Stein GM, Stettin A, Schultze J, Berg PA: Induction of anti-mistletoe lectin antibodies in relation to different mistletoe-extracts. Anticancer Drugs 1997;8(suppl 1):S57-S59.
111. Stettin A, Schultze JL, Stechemesser E, Berg PA: Anti-mistletoe lectin antibodies are produced in patients during therapy with an aqueous mistletoe extract derived from Viscum album L. and neutralize lectin-induced cytotoxicity in vitro. Klin Wochenschr 1990;68:896-900.
112. Yoon TJ, Yoo YC, Kang TB, Song SK, Lee KB, Her E, Song KS, Kim JB: Antitumor activity of the Korean mistletoe lectin is attributed to activation of macrophages and NK cells. Arch Pharm Res 2003;26:861-867.
113. Muthing J, Burg M, Mockel B, Langer M, Metelmann-Strupat W, Werner A, Neumann U, Peter-Katalinic J, Eck J: Preferential binding of the anticancer drug rViscumin (recombinant mistletoe lectin) to terminally alpha2-6-sialylated neolacto-series gangliosides. Glycobiology 2002;12:485-497.
114. Muthing J, Meisen I, Bulau P, Langer M, Witthohn K, Lentzen H, Neumann U, Peter-Katalinic J: Mistletoe lectin I is a sialic acid-specific lectin with strict preference to gangliosides and glycoproteins with terminal Neu5Ac alpha 2-6Gal beta 1-4GlcNAc residues. Biochemistry 2004;43:2996-3007.
115. Bergmann L, Aamdal S, Marreaud S, Lacombe D, Herold M, Yamaguchi T, Wilhelm-Ogunbiyi K, Lentzen H, Zwierzina H: Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: a study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001). Eur J Cancer 2008;44:1657-1662.
116. Eichler W: Characteristics of two CD75-related cell-surface expressed antigens of human lymphocytes. Mol Immunol 2007;44:2047-2055.
117. Distler U, Souady J, Hulsewig M, Drmic-Hofman I, Haier J, Denz A, Grutzmann R, Pilarsky C, Senninger N, Dreisewerd K, Berkenkamp S, Schmidt MA, Peter-Katalinic J, Muthing J: Tumor-associated CD75s- and iso-CD75s-gangliosides are potential targets for adjuvant therapy in pancreatic cancer. Mol Cancer Ther 2008;7:2464-2475.
118. Muthing J, Meisen I, Kniep B, Haier J, Senninger N, Neumann U, Langer M, Witthohn K, Milosevic J, Peter-Katalinic J: Tumor-associated CD75s gangliosides and CD75s-bearing glycoproteins with Neu5Acalpha2-6Galbeta1-4GlcNAc-residues are receptors for the anticancer drug rViscumin. FASEB J 2005;19:103-105.
119. Zimring JC, Levery SB, Kniep B, Kapp LM, Fuller M, Kapp JA: CD75s is a marker of murine CD8(+) suppressor T cells. Int Immunol 2003;15:1389-1399.
120. Hajto T, Hostanska K, Berki T, Palinkas L, Boldizsar F, Nemeth P: Oncopharmacological perspectives of a plant lectin (Viscum album agglutinin-I): overview of recent results from in vitro experiments and in vivo animal models, and their possible relevance for clinical applications. Evid Based Complement Alternat Med 2005;2:59-67.
121. Hajto T: Immunologische Aspekte bei der klinischen Anwendung von Mistelpräparaten. Mistilteinn 2005/6 2005;6:44-53.
122. Elsasser-Beile U, Voss M, Schuhle R, Wetterauer U: Biological effects of natural and recombinant mistletoe lectin and an aqueous mistletoe extract on human monocytes and lymphocytes in vitro. J Clin Lab Anal 2000;14:255-259.
123. Huber R, Rostock M, Goedl R, Ludtke R, Urech K, Buck S, Klein R: Mistletoe treatment induces GM-CSF- and IL-5 production by PBMC and increases blood granulocyte- and eosinophil counts: a placebo controlled randomized study in healthy subjects. Eur J Med Res 2005;10:411-418.
124. Kovacs E: Effects of Viscum album extract therapy in patients with cancer: relation with interleukin-6, soluble interleukin-6 receptor, and soluble gp130. J Altern Complement Med 2004;10:241-246.
125. Stein GM: Untersuchungen zur Interaktion von Mistelantigenen mit dem Immunsystem. Dissertation, Eberhard-Karls-Universität Tübingen, 1995; 1-216.
126. Stein GM, Berg PA: Evaluation of the stimulatory activity of a fermented mistletoe lectin-1 free mistletoe extract on T-helper cells and monocytes in healthy individuals in vitro. Arzneimittelforschung 1996;46:635-639.
127. Stein GM, Berg PA: Mistletoe extract-induced effects on immunocompetent cells: in vitro studies. Anticancer Drugs 1997;8(suppl 1):S39-S42.
128. Bashyam H: Interleukin-12: A master regulator. J Exp Med 2007.
129. Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-146.
130. Van Huyen JP, Delignat S, Bayry J, Kazatchkine MD, Bruneval P, Nicoletti A, Kaveri SV: Interleukin-12 is associated with the in vivo anti-tumor effect of mistletoe extracts in B16 mouse melanoma. Cancer Lett 2006;243:32-37.
131. Long EO: Ready for prime time: NK cell priming by dendritic cells. Immunity 2007;26:385-387.
132. Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A: Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 2007;26:503-517.
133. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y: Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004;202:275-293.
134. Melamed R, Bar-Yosef S, Shakhar G, Shakhar K, Ben Eliyahu S: Suppression of natural killer cell activity and promotion of tumor metastasis by ketamine, thiopental, and halothane, but not by propofol: mediating mechanisms and prophylactic measures. Anesth Analg 2003;97:1331-1339.
135. Klatte T, Ittenson A, Rohl FW, Ecke M, Allhoff EP, Bohm M: Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial. Br J Cancer 2006;95:1167-1173.
136. Oosterling SJ, van der Bij GJ, Mels AK, Beelen RH, Meijer S, van Egmond M, van Leeuwen PA: Perioperative IFN-alpha to avoid surgically induced immune suppression in colorectal cancer patients. Histol Histopathol 2006;21:753-760.
137. Khan AL, Richardson S, Drew J, Larsen F, Campbell M, Heys SD, Ah-See AK, Eremin O: Polyadenylic-polyuridylic acid enhances the natural cell-mediated cytotoxicity in patients with breast cancer undergoing mastectomy. Surgery 1995;118:531-538.
138. Li Y, Yang GL, Yuan HY, Bai DJ, Wang K, Lin CR, Hu MB, Feng MH: Effects of perioperative cimetidine administration on peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer: results of a randomized controlled clinical trial. Hepatogastro-enterology 2005;52:504-508.
139. Kimura M, Sasada T, Kanai M, Kawai Y, Yoshida Y, Hayashi E, Iwata S, Takabayashi A: Preventive effect of a traditional herbal medicine, Hochu-ek-ki-to, on immunosuppression induced by surgical stress. Surg Today 2008;38:316-322.
140. Rosenne E, Shakhar G, Melamed R, Schwartz Y, Erdreich-Epstein A, Ben Eliyahu S: Inducing a mode of NK-resistance to suppression by stress and surgery: a potential approach based on low dose of poly I-C to reduce postoperative cancer metastasis. Brain Behav Immun 2007;21:395-408.
141. Patel H, Le Marer N, Wharton RQ, Khan ZA, Araia R, Glover C, Henry MM, Allen-Mersh TG: Clearance of circulating tumor cells after excision of primary colorectal cancer. Ann Surg 2002;235:226-231.
142. O'Hanlon LH: Natural born killers: NK cells drafted into the cancer fight. J Natl Cancer Inst 2004;96:651-653.
143. Pross HF, Lotzova E: Role of natural killer cells in cancer. Nat Immun 1993;12:279-292.
144. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-2100.
145. Smyth MJ, Teng MW, Swann J, Kyparissoudis K, Godfrey DI, Hayakawa Y: CD4+CD25+ T regulatory cells suppress NK cell-mediated immuno-therapy of cancer. J Immunol 2006;176:1582-1587.